检索结果-南通市图书馆

Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Nanjing Medical University 2009年第6期23卷 392-397页

作者： yongmei yin Yiting Geng Xiaodong Li Xiaoli Hu Xiaofeng Chen Wei Li Yongqian Shu Department of Oncology the First Affiliated Hospital of Nanjing Medical University Nanjing 210029 China

Objective： To assess the efficacy and toxicity of gefitinib as a single agent treatment in Chinese patients with advanced non-small cell lung cancer （NSCLC）. Methods： Forty-five patients with advanced NSCLC were treated with gefitinib at 250 mg daily until the disease progressed or the patient could not tolerate the toxicity. Results： None of the patients achieved a complete response （CR）, while 15 patients achieved a partial remission （PR） and 17 experienced a stable disease （SD）. Thirteen patients continued to have a progressive disease （PD）. The response rate and the disease control rate were 33.3% and 71.1%, respectively. The symptom remission rate was 72.5%, and the median remission time was 8 days. The median survival time was 15.3 months. The median progression-free survival time was 6.0 months. The most common toxicities included rash （53.3%） and diarrhea （33.3%）. Dehydration and pruritus of the skin developed in 26.7% and 22.2% of the patients, respectively. Hepatic toxicity occurred in 6.7% of patients and oral ulceration occurred in 4.4% of patients. Conclusion： Single agent treatment with gefitinib is effective against advanced NSCLC, and is well tolerated in Chinese patients.

关键词： gefitinib non-small cell lung cancer (NSCLC) first-line treatment

TNF-alpha-induced metastasis gene changes in MCF-7 cells

在线全文

学校读者我要写书评

暂无评论

Journal of Nanjing Medical University 2008年第6期22卷 366-371页

作者： Xiaofeng Chen Yongqian Shu Wei Li yongmei yin Department of Oncology the First Affiliated Hospital of Nanjing Medical University Nanjing 210029 Jiangsu province China

Objective： Studies have shown that TNF- α secreted by tumor ceils and macrophages infiltrated into the tumor microenvironment might promote the metastasis of a variety of malignant cancers, including breast cancer. The present study was designed to detect global metastasis-related gene expression changes of MCF-7 cells treated by low dose TNF-α and to further explore the mechanisms by which TNF- α contributes to metastasis. Methods： MCF-7 cells were cultured and treated with low dose TNF-α （20 ng/ml）, cDNA array analysis was applied to detect the metastasis related gene expressions. Results： A total of 36 gene expressions were significantly regulated by TNF- α. Functional analysis indicates that the altered genes belong to different functional group. Most of the genes changed may promote the metastasis of MCF-7 cells while the others may inhibit metastasis. The changes observed in gene expression following TNF-α were somewhat time dependent. Conclusion： TNF-α can enhance the invasive ability of MCF-7 cells, partly by regulating a series of metastasis related genes, and these genes may take part in every step of metastasis. Some of the genes deserve further study.

关键词： Tumor necrosis factor-α metastasis cDNA array

2018年中国临床肿瘤学会乳腺癌治疗指南更新要点

在线全文

学校读者我要写书评

暂无评论

中华医学杂志 2018年第16期98卷 1213-1217页

作者：黄香殷咏梅南京医科大学第一附属医院肿瘤科 210029

中国临床肿瘤学会（CSCO）《乳腺癌诊疗指南》是一部立足于循证医学证据和精准医学基本原则，结合国内外医疗前沿进展，同时兼顾中国的医疗现状和资源可及性的临床诊疗指南。科学性与实践性为指南的两大考量原则，每一个临床问题的诊治... 详细信息

中国临床肿瘤学会（CSCO）《乳腺癌诊疗指南》是一部立足于循证医学证据和精准医学基本原则，结合国内外医疗前沿进展，同时兼顾中国的医疗现状和资源可及性的临床诊疗指南。科学性与实践性为指南的两大考量原则，每一个临床问题的诊治建议分为基本策略和可选策略两部分。基本策略属于可及性好的普适性诊治措施，肿瘤治疗价值相对稳定；可选策略多属于已有高级别证据，但可及性差或效价比超出国人承受能力的药物或治疗措施。

关键词：临床肿瘤学会治疗指南乳腺癌中国循证医学证据诊疗指南医疗现状临床问题

Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2023年第12期136卷 1459-1467页

作者： Yang Yuan Shaohua Zhang Tao Wang Li Bian Min Yan yongmei yin Yuhua Song Yi Wen Jianbin Li Zefei Jiang Department of Oncology No.4 Ward The Fifth Medical Center of Chinese People’s Liberation Army(PLA)General HospitalBeijing 100071China Department of Oncology No.3 Ward The Fifth Medical Center of Chinese People’s Liberation Army(PLA)General HospitalBeijing 100071China Department of Breast Disease Henan Breast Cancer CenterThe Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer HospitalZhengzhouHenan 450008 China Department of Breast Cancer Jiangsu Province Hospital&The First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsu 210029 China Department of Breast Cancer Center The Affiliated Hospital of Qingdao UniversityQingdaoShandong 260000 China Medical Department Medpion(Beijing)Medical Technology Co.LtdBeijing 100062 China

Background:Endocrine therapy(ET)and ET-based regimens are the preferred first-line treatment options for hormone receptor(HR)-positive and human epidermal growth factor receptor 2(HER2)-negative metastatic breast cancer(HR+/HER2-MBC),while chemotherapy(CT)is commonly used in clinical *** aim of this study was to investigate the efficacy and clinical outcome of ET and CT as first-line treatment in Chinese patients with HR+/***:Patients diagnosed with HR+/HER2-MBC between January 1st,1996 and September 30th,2018 were screened from the Chinese Society of Clinical Oncology Breast Cancer *** initial and maintenance first-line treatment,progression-free survival(PFS),and overall survival(OS)were ***:Among the 1877 included patients,1215(64.7%)received CT and 662(35.3%)received ET as initial first-line *** were no statistically significant differences in PFS and OS between patients receiving ET and CT as initial first-line treatment in the total population(PFS:12.0 vs.11.0 months,P=0.22;OS:54.0 vs.49.0 months,P=0.09)and propensity score matched *** patients without disease progression after at least 3 months of initial therapy,maintenance ET following initial CT(CT-ET cohort,n=449)and continuous schedule of ET(ET cohort,n=527)had longer PFS than continuous schedule of CT(CT cohort,n=406)in the total population(CT-ET cohort *** cohort:17.0 vs.8.5 months;P<0.01;ET cohort *** cohort:14.0 vs.8.5 months;P<0.01)and propensity score matched *** in the three cohorts yielded the same results as ***:ET was associated with similar clinical outcome to CT as initial first-line *** patients without disease progression after initial CT,switching to maintenance ET showed superiority in clinical outcome over continuous schedule of CT.

关键词： Breast neoplasms Metastatic breast cancer Hormone receptor-positive HER2-negative Chemotherapy Endocrine therapy First-line treatment Maintenance therapy

晚期乳腺癌内分泌分层治疗策略:分层施治、靶向优先

在线全文

学校读者我要写书评

暂无评论

中华医学杂志 2023年第34期103卷 2657-2661页

作者：黄香金楠殷咏梅南京医科大学第一附属医院肿瘤科南京210029

激素受体(HR)阳性人表皮生长因子受体2(HER2)阴性乳腺癌的内分泌治疗已进入靶向联合时代,以细胞周期蛋白依赖性激酶4/6抑制剂(CDK4/6i)为首的众多靶向药物纷纷崭露头角,为HR阳性HER2阴性晚期乳腺癌患者提供了丰富的治疗选择。为适应我... 详细信息

激素受体(HR)阳性人表皮生长因子受体2(HER2)阴性乳腺癌的内分泌治疗已进入靶向联合时代,以细胞周期蛋白依赖性激酶4/6抑制剂(CDK4/6i)为首的众多靶向药物纷纷崭露头角,为HR阳性HER2阴性晚期乳腺癌患者提供了丰富的治疗选择。为适应我国临床诊疗背景、规范靶向药物的合理使用,中国临床肿瘤学会(CSCO)乳腺癌诊疗指南遵循循证医学证据,兼顾药物可及性,形成晚期乳腺癌内分泌分层治疗策略,为临床肿瘤医生提供科学、有序的决策指导。

关键词：乳腺肿瘤内分泌治疗分层治疗

在线全文

学校读者我要写书评

暂无评论

乳腺肿瘤心脏病学的研究现状与争议

中国癌症杂志 2020年第6期30卷 475-480页

作者：杨艺琦吴昊(综述) 殷咏梅(审校) 南京医科大学江苏南京210029 南京医科大学第一附属医院肿瘤科江苏南京210029

乳腺癌是女性最常见的恶性肿瘤,也是女性癌症死亡主要的原因,各种治疗方式在提高乳腺癌患者生存率的同时,其心脏毒性也逐渐引起人们的重视。然而近年来也有部分研究发现,抗肿瘤药物并没有显著增加患者心血管疾病的死亡率。就乳腺癌患者... 详细信息

乳腺癌是女性最常见的恶性肿瘤,也是女性癌症死亡主要的原因,各种治疗方式在提高乳腺癌患者生存率的同时,其心脏毒性也逐渐引起人们的重视。然而近年来也有部分研究发现,抗肿瘤药物并没有显著增加患者心血管疾病的死亡率。就乳腺癌患者心血管系统疾病的研究现状和争议综述,以期为关注这一领域的临床研究者提供一些思路。

关键词：乳腺癌肿瘤心脏病学心脏毒性心血管疾病

Conserved immuno-collagenic subtypes predict response to immune checkpoint blockade

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2024年第5期44卷 554-575页

作者： Jie Mei Yun Cai Rui Xu Qing Li Jiahui Chu Zhiwen Luo Yaying Sun Yuxin Shi Junying Xu Di Li Shuai Liang ying Jiang Jiayu Liu Zhiwen Qian Jiaofeng Zhou Mengyun Wan Yunlong Yang Yichao Zhu Yan Zhang yongmei yin Department of Oncology The First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuP.R.China The First Clinical Medicine College Nanjing Medical UniversityNanjingJiangsuP.R.China Departments of Gynecology Wuxi Maternal and Child Health Care HospitalWuxi Medical CenterNanjing Medical UniversityWuxiJiangsuP.R.China Departments of Oncology Xuzhou Central HospitalThe Xuzhou School of Clinical Medicine of Nanjing Medical UniversityXuzhouJiangsuP.R.China Department of Sports Medicine Huashan Hospital Affiliated to Fudan UniversityShanghaiP.R.China Department of Sports Medicine Shanghai General HospitalShanghai Jiao Tong University School of MedicineShanghaiP.R.China Departments of Oncology The AffiliatedWuxi People’s Hospital of Nanjing Medical UniversityWuxi Medical CenterNanjing Medical UniversityWuxiJiangsuP.R.China Shanghai Outdo Biotech Co. Ltd.National Engineering Center for BiochipShanghaiP.R.China Departments of Gynecology Wuxi Maternity and Child Health Care HospitalAffiliatedWomen’s Hospital of Jiangnan UniversityWuxiJiangsuP.R.China Department of Physiology School of Basic Medical SciencesNanjing Medical UniversityNanjingJiangsuP.R.China Department of Cellular and Genetic Medicine School of Basic Medical SciencesFudan UniversityShanghaiP.R.China Jiangsu Key Lab of Cancer Biomarkers Prevention and TreatmentCollaborative Innovation Center for Personalized Cancer MedicineNanjing Medical UniversityNanjingJiangsuP.R.China

Background:Immune checkpoint blockade(ICB)has revolutionized the treatment of various cancer *** significant preclinical advancements in understanding mechanisms,identifying the molecular basis and predictive biomarkers for clinical ICB responses remains *** evidence,both preclinical and clinical,underscores the pivotal role of the extracellular matrix(ECM)in modulating immune cell infiltration and *** study aimed to create an innovative classifier that leverages ECM characteristics to enhance the effectiveness of ICB ***:We analyzed transcriptomic collagen activity and immune signatures in 649 patients with cancer undergoing ICB *** analysis led to the identification of three distinct immuno-collagenic subtypes predictive of ICB *** validated these subtypes using the transcriptome data from 9,363 cancer patients from The Cancer Genome Atlas(TCGA)dataset and 1,084 inhouse ***,novel therapeutic targets were identified based on these established immuno-collagenic ***:Our categorization divided tumors into three subtypes:“soft&hot”(low collagen activity and high immune infiltration),“armored&cold”(high collagen activity and low immune infiltration),and“quiescent”(low collagen activity and immune infiltration).Notably,“soft&hot”tumors exhibited the most robust response to ICB therapy across various cancer ***,inhibiting collagen augmented the response to ICB in preclinical ***,these subtypes demonstrated associations with immune activity and prognostic predictive potential across multiple cancer ***,an unbiased approach identified B7 homolog 3(B7-H3),an available drug target,as strongly expressed in“armored&cold”tumors,relating with poor ***:This study introduces histopathology-based universal immunocollagenic subtypes capable of predicting ICB responses across diverse cancer *** findings offer insights

关键词： collagen deposition immune infiltration immunotherapy pan-cancer tumor microenvironment

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

原子吸收分光光度法测铬浸取液中的钙含量

无机盐工业 2007年第9期39卷 57-59页

作者：殷咏梅许红李鑫济南裕兴化工有限责任公司山东济南250033

作为铬盐生产中间产品的浸取液,其钙含量的高低对后续生产工序有着重要影响,因而需要加以控制。若用容量法测定,因其中钙含量太低,不仅操作繁琐,时间长,且重现性差,而且误差较大。用原子吸收分光光度法测铬浸取液中的钙含量,方法简单、... 详细信息

作为铬盐生产中间产品的浸取液,其钙含量的高低对后续生产工序有着重要影响,因而需要加以控制。若用容量法测定,因其中钙含量太低,不仅操作繁琐,时间长,且重现性差,而且误差较大。用原子吸收分光光度法测铬浸取液中的钙含量,方法简单、快速,在优化条件下,加标回收率为98.3%～103.3%,足以满足控制铬浸取液中钙含量的要求。对减少工艺过程中的结壁现象、降低消耗,起着重要作用。

关键词：铬盐浸取液钙含量原子吸收分光光度法

预见性护理干预对脑出血急性期患者预防便秘的临床效果观察

在线全文

学校读者我要写书评

暂无评论

中国社区医师 2017年第19期33卷 144-145页

作者：尹咏梅平邑县中医医院 273300

目的:探讨预见性护理干预对脑出血急性期患者便秘的效果。方法:收治脑出血急性期患者110例,随机分为对照组和观察组。对照组采用常规护理,观察组采用预见性护理干预,比较两组护理效果。结果:观察组便秘情况和并发症发生率明显优于对照组... 详细信息

目的:探讨预见性护理干预对脑出血急性期患者便秘的效果。方法:收治脑出血急性期患者110例,随机分为对照组和观察组。对照组采用常规护理,观察组采用预见性护理干预,比较两组护理效果。结果:观察组便秘情况和并发症发生率明显优于对照组(P<0.05)。结论:预见性护理干预能够有效地改善脑出血急性期患者便秘和并发症发生率,提高患者依从性和治疗效果。

关键词：预见性护理干预脑出血急性期便秘